Alkermes (ALKS) EPS (Diluted) Growth (3y) (2013 - 2026)
Alkermes (ALKS) EPS (Diluted) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 50.12% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 6.26% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -70.43% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.24% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -6.96% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 64.19% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -18.62% |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -21.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.85% |
| Dec 31, 2025 | 2.20% |
| Dec 31, 2024 | -93.27% |
| Sep 30, 2024 | 74.78% |
| Jun 30, 2024 | -49.46% |
| Mar 31, 2024 | 55.72% |
| Dec 31, 2023 | -8.88% |
| Sep 30, 2023 | -578.82% |
| Jun 30, 2023 | -9.78% |
| Mar 31, 2023 | 5.13% |
| Dec 31, 2022 | 225.48% |
| Sep 30, 2022 | -3.19% |
| Jun 30, 2022 | 13.22% |
| Mar 31, 2022 | 30.07% |
| Dec 31, 2021 | 147.05% |
| Sep 30, 2021 | 8.04% |
| Jun 30, 2021 | 27.36% |
| Mar 31, 2021 | 30.41% |
| Dec 31, 2020 | -41.66% |
| Sep 30, 2020 | 84.86% |